ANI Pharmaceuticals’ rare disease franchise, led by Cortrophin Gel, drove significant growth in 2025. Sales of Cortrophin Gel soared 70% to $236 million in the first nine months, with continued growth in prescriptions. ANIP expects rare disease business to account for half of total net revenues in 2025, projecting sales to reach $347-$352 million.

ANIP faces competition in the ophthalmology space from AbbVie and Regeneron. AbbVie’s Ozurdex competes directly with Iluvien and Yutiq, while Regeneron’s Eylea is a major player in DME. ANIP’s main competitor for Cortrophin Gel is Acthar Gel by Keenova, which raised its 2025 sales outlook.

ANI Pharmaceuticals’ shares have surged 42.3% in a year, outperforming the industry. The stock trades at a premium to the industry based on the price/sales ratio. EPS estimates for 2025 and 2026 have risen, and ANIP currently holds a Zacks Rank #1 (Strong Buy). The company is well-positioned for growth in the pharmaceutical sector.

The convergence of artificial intelligence and quantum computing presents lucrative investment opportunities. Position your portfolio for success with the latest report on quantum computing stocks. Discover the potential winners in the quantum computing race and capitalize on this technological revolution for substantial gains. Access the free report now to stay ahead in the market.

Read more at Nasdaq: Will ANIP’s Rare Disease Franchise Maintain Momentum in 2026?